Transplantation

The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them…

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately 30% of patients with acute myeloid leukemia (AML) and…

Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of…

Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for…

Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence…

Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;…

Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease…

The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…

Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not…

Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…

Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared…

Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults…